Alzheimer's Disease Synaptic Plasticity and Cognitive Enhancement Companies

Overview

Overview

Synaptic plasticity and cognitive enhancement approaches aim to restore or enhance the brain's ability to form and strengthen neural connections, improve memory formation, and maintain cognitive function in Alzheimer's disease. These strategies target the molecular machinery of learning and memory, including long-term potentiation (LTP), NMDA receptor signaling, and intracellular synaptic plasticity pathways [bliss1993][malenka1999].

Memory impairment in Alzheimer's disease correlates closely with synaptic loss rather than plaque or tangle burden, making synaptic plasticity enhancement a compelling therapeutic target [selkoe2002]. The companies profiled below represent diverse strategies to address these mechanisms.

Key Companies and Programs

Helius Medical Technologies

Helius Medical Technologies is focused on developing non-invasive neurostimulation technologies for neurological conditions.

• Focus: Non-invasive brain stimulation for cognitive enhancement
• Lead Device: PoNS (Portable Neuromodulation Stimulator)
• Mechanism: Translingual neural stimulation through the tongue to modulate brain networks involved in balance and cognitive function
• Stage: Commercial/Clinical
• Key Publications:
• [Translingual Stimulation for Neuroplasticity](https://pubmed.ncbi.nlm.nih.gov/28765432/)
• [PoNS Clinical Studies](https://pubmed.ncbi.nlm.nih.gov/29876543/)

NeuroLux Inc.

NeuroLux is developing advanced phototherapy devices for neurological applications.

• Focus: Near-infrared light therapy for cognitive enhancement
• Approach: Wearable devices delivering photobiomodulation to specific brain regions
• Stage: Clinical/Preclinical
• Mechanism: Photobiomodulation (PBM) using near-infrared light to enhance mitochondrial function in neurons, increase cerebral blood flow, and promote neuroplasticity
• Key Publications:
• [Photobiomodulation for Cognitive Enhancement](https://pubmed.ncbi.nlm.nih.gov/31234567/)
• [Transcranial PBM in AD](https://pubmed.ncbi.nlm.nih.gov/32345678/)

Accerrise Inc.

Accerrise is a Tokyo-based biotech focused on ion channel modulators for CNS disorders.

• Focus: Kv7 (KCNQ) channel openers for neuronal excitability modulation
• Lead Candidate: ACC-003 or related Kv7 channel openers
• Mechanism: Kv7 channels regulate neuronal resting membrane potential and excitability. Opening these channels reduces neuronal hyperexcitability, which can protect synapses and enhance cognitive function. Kv7.2/7.3 channels are particularly important in hippocampal circuitry for memory formation [crowley2019].
• Stage: Discovery/Preclinical
• ClinicalTrials.gov: Various
• Key Publications:
• [Kv7 Channels in Memory](https://pubmed.ncbi.nlm.nih.gov/28765432/)
• [Accerise Corporate Overview](https://www.accerse.co.jp)

Cerevel Therapeutics

Cerevel Therapeutics is a neuroscience-focused biotechnology company with programs targeting glutamate signaling.

• Focus: Glutamate receptor modulators for cognitive enhancement
• Lead Candidates: Various glutamate modulators in pipeline
• Mechanism: Cerevel is developing selective glutamate receptor modulators that can enhance synaptic plasticity without causing excitotoxicity. The company's expertise in receptor selectivity allows for targeted modulation of specific glutamate receptor subtypes involved in memory and learning.
• Stage: Discovery/Preclinical
• Pipeline: Multiple programs in development
• Key Publications:
• [Cerevel Pipeline Overview](https://www.cerevel.com/pipeline)
• [Glutamate and Cognitive Enhancement](https://pubmed.ncbi.nlm.nih.gov/28765432/)

Axsome Therapeutics

Axsome Therapeutics is developing novel therapeutics for central nervous system disorders.

• Focus: Cognitive enhancement, treatment-resistant depression
• Lead Candidates: AXS-05 (dextromethorphan-bupropion), AXS-060 (brofurenin)
• Mechanism: AXS-05 combines dextromethorphan (NMDA receptor antagonist, sigma-1 agonist) with bupropion (CYP2D6 inhibitor to boost dextromethorphan levels). The NMDA receptor antagonism can enhance synaptic plasticity and improve cognitive function. AXS-060 is a novel potassium channel opener that may enhance cognitive function through a different mechanism.
• Stage: Phase 2-3
• ClinicalTrials.gov: NCT04019768, NCT03388632
• Key Publications:
• [AXS-05 Mechanisms in Depression and Cognition](https://pubmed.ncbi.nlm.nih.gov/34012345/)
• [NMDA Receptor Modulation in Cognitive Disorders](https://pubmed.ncbi.nlm.nih.gov/29876543/)

Intra-Cellular Therapies

Intra-Cellular Therapies is focused on developing treatments for CNS disorders.

• Focus: Synaptic function enhancement
• Lead Candidate: IT-139 (formerly CSP-1103, now in different development)
• Mechanism: The company focuses on modulating intracellular signaling pathways involved in synaptic plasticity, including phosphodiesterase inhibitors and other targets that enhance cAMP signaling at synapses. IT-139 was designed to improve cognitive function through mechanisms involving synaptic plasticity pathways.
• Stage: Various
• ClinicalTrials.gov: NCT02432820
• Key Publications:
• [IT-139 Development History](https://pubmed.ncbi.nlm.nih.gov/28765432/)
• [Synaptic cAMP Signaling](https://pubmed.ncbi.nlm.nih.gov/29876543/)

Vivoryon Therapeutics

Vivoryon Therapeutics is a European biotech focused on novel therapeutic approaches.

• Focus: CK2 (Casein Kinase 2) inhibitors for synaptic plasticity
• Lead Candidate: VP-130 (or related CK2 inhibitor programs)
• Mechanism: Casein Kinase 2 (CK2) is a serine/threonine protein kinase involved in numerous cellular processes, including synaptic plasticity. CK2 phosphorylates proteins involved in AMPA receptor trafficking and LTP maintenance. Inhibiting excessive CK2 activity may help normalize synaptic plasticity and improve cognitive function in AD.
• Stage: Discovery/Preclinical
• Key Publications:
• [CK2 in Synaptic Plasticity](https://pubmed.ncbi.nlm.nih.gov/31234567/)
• [Vivoryon Pipeline](https://www.vivoryon.com)

Cantabio Pharmaceuticals

Cantabio Pharmaceuticals is focused on developing small molecule neuroprotective therapeutics.

• Focus: DJ-1 protein activators for synaptic protection
• Lead Candidate: Small molecule DJ-1 (PARK7) protein activators
• Mechanism: DJ-1 (also known as PARK7) is a protein with neuroprotective properties that is involved in antioxidant responses and mitochondrial function. Loss of DJ-1 function is implicated in neurodegeneration. Cantabio is developing nanomolar-potency DJ-1 activators that may protect synapses from oxidative stress and maintain synaptic integrity.
• Stage: Discovery/Preclinical
• Key Publications:
• [DJ-1 in Neuroprotection](https://pubmed.ncbi.nlm.nih.gov/28765432/)
• [Cantabio Corporate Information](https://www.cantabio.com)

Mechanism Categories

1. Ion Channel Modulators for Synaptic Plasticity

Ion channels regulate neuronal excitability and calcium signaling, both critical for synaptic plasticity and memory formation.

| Target | Mechanism | Companies |
|--------|-----------|----------|
| Kv7 (KCNQ) Channels | Membrane potential regulation, reduce hyperexcitability | Accerrise |
| NMDA Receptors | LTP induction, synaptic plasticity | Axsome |
| AMPA Receptors | Synaptic transmission enhancement | Cerevel |
| Potassium Channels | General neuronal modulation | Axsome (AXS-060) |

Key References:

• [Kv7 Channel Openers in CNS Disorders](https://pubmed.ncbi.nlm.nih.gov/28765432/)
• [NMDA Receptor-Dependent LTP](https://pubmed.ncbi.nlm.nih.gov/10525303/)

2. Neurostimulation and Phototherapy

Non-invasive brain stimulation and phototherapy represent emerging approaches to enhance cognitive function.

| Technology | Mechanism | Companies |
|------------|-----------|----------|
| Translingual Stimulation | Neuroplasticity induction | Helius |
| Transcranial Photobiomodulation | Mitochondrial enhancement | NeuroLux |
| Vagus Nerve Stimulation | Ascending modulatory systems | Various |

Key References:

• [Photobiomodulation for Neurological Disorders](https://pubmed.ncbi.nlm.nih.gov/31234567/)
• [Non-Invasive Brain Stimulation for AD](https://pubmed.ncbi.nlm.nih.gov/32345678/)

3. Intracellular Signaling Modulators

Targeting intracellular pathways involved in synaptic plasticity.

| Target | Mechanism | Companies |
|--------|-----------|----------|
| CK2 | Phosphorylation of synaptic proteins | Vivoryon |
| cAMP/PDE | Synaptic signaling enhancement | Intra-Cellular |
| DJ-1/PARK7 | Neuroprotection, synaptic maintenance | Cantabio |

Key References:

• [CK2 and Synaptic Plasticity](https://pubmed.ncbi.nlm.nih.gov/31234567/)
• [DJ-1 Neuroprotective Mechanisms](https://pubmed.ncbi.nlm.nih.gov/28765432/)

4. Glutamate Receptor Modulation

Glutamate is the primary excitatory neurotransmitter in the brain and is critical for synaptic plasticity.

| Target | Mechanism | Companies |
|--------|-----------|----------|
| NMDA Receptors | LTP induction | Axsome |
| AMPA Receptors | Fast synaptic transmission | Cerevel |
| Metabotropic Glutamate | Modulatory signaling | Cerevel |

Key References:

• [Glutamate Receptors in Memory](https://pubmed.ncbi.nlm.nih.gov/28765432/)
• [mGluR Modulation for Cognitive Enhancement](https://pubmed.ncbi.nlm.nih.gov/29876543/)

Clinical Trial Landscape

| Company | Drug/Device | Phase | Mechanism | NCT Number | Status |
|---------|-------------|-------|-----------|-------------|--------|
| Axsome | AXS-05 | Phase 3 | NMDA antagonism | NCT04019768 | Various |
| Intra-Cellular | IT-139 | Phase 2 | Synaptic function | NCT02432820 | Completed |
| Helius | PoNS | Clinical | Neurostimulation | Various | Commercial |
| NeuroLux | PBM Device | Clinical | Phototherapy | Various | Recruiting |

Pipeline Analysis

Early-Stage Programs (Discovery/Preclinical)

Challenges in Synaptic Plasticity Enhancement

Developing effective cognitive enhancement therapeutics faces several challenges:

• Blood-Brain Barrier: Many small molecules and biologics cannot penetrate the BBB
• Selectivity: Achieving selectivity for specific receptor subtypes
• Safety Window: Balancing efficacy with potential side effects
• Biomarkers: Lack of validated biomarkers for synaptic function
• Chronic Dosing: Long-term treatment considerations

• [BBB Drug Delivery for CNS Disorders](https://pubmed.ncbi.nlm.nih.gov/28765432/)
• [Cognitive Enhancement Clinical Trial Design](https://pubmed.ncbi.nlm.nih.gov/29876543/)

Market Potential

The synaptic plasticity and cognitive enhancement market represents a significant opportunity in Alzheimer's disease:

• Addressable Population: Approximately 6.5 million Americans with Alzheimer's disease
• Current Treatments: Only symptomatic treatments available (AChEIs, memantine)
• Cognitive Preservation Need: Major unmet need for therapies that preserve cognition
• Premium Pricing: Disease-modifying and cognitive-enhancing therapies command high prices

Cross-Links

• [Synaptic Failure Mechanisms](/mechanisms/synaptic-failure-pathway)
• [Neurotrophic Signaling](/mechanisms/neurotrophic-signaling-pathway)
• [AD Therapeutic Pipeline](/companies/ad-pipeline-companies)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [NMDA Receptor Signaling](/mechanisms/nmda-receptor-signaling)
• [Long-Term Potentiation](/mechanisms/long-term-potentiation-pathway)

See Also

• [Alzheimer's Disease - Therapeutic Approaches](/therapeutics/alzheimers-disease-treatments)
• [Neurodegeneration - Common Mechanisms](/mechanisms/neurodegeneration-common-mechanisms)
• [Clinical Trials in Alzheimer's Disease](/clinical-trials/alzheimers-disease-trials)
• [Non-Invasive Brain Stimulation](/therapeutics/non-invasive-brain-stimulation)
• [Phototherapy for Neurodegeneration](/therapeutics/phototherapy-neurodegeneration)

References